Chiral of D-type mesoporous silica deliver anti-inflammatory drug with double synergism

Chiral drug delivery systems have gained great attention in novel drug delivery applications. To explore their exceptional functions, a series of chiral mesoporous silica xerogel (L-SX, D-SX) was constructed using biomimetic method and another series of chiral mesoporous silica nanoparticles (L-MSNs, D-MSNs) were established by applying chiral grafting method. Poorly water-soluble celecoxib (CXB) was chosen to load into these chiral carriers as well as corresponding control carrier, and further to study characteristics and delivery effects of drug loaded carriers. The results indicated that all these chiral carriers formed hydrogen bonds with drugs and can successfully convert drug crystal phase to amorphous state so as to enhance drug dissolution compared to raw drug. In vivo pharmacokinetics and pharmacodynamics results demonstrated that D-SX and D-MSNs turned out to be the best CXB carriers possibly owing to their chiral grafted groups and therefore obtaining double synergism of drug delivery enhancement and superior anti-inflammation effect, which can significantly revolutionize anti-inflammatory drug treatment. • Chiral mesoporous silica xerogel was originally established using chiral threonine • Chiral mesoporous silica nanoparticles were firstly formed by chiral tartaric acid • D-type mesoporous silica delivered celecoxib with superior anti-inflammatory effect • D-type mesoporous silica achieved higher drug bioavailability than some reports